RxDoctor Payments Data

Danny Barlev, MD

Dermatology · Cleveland, OHNPI 1285991372

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 96.1% of the total across 33 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 14 manufacturers, the largest accounting for just 17.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $442, 9.8 times the $45 reported in 2019. That places this record below the midpoint for dermatology clinicians in OH, where the typical reported total is $2,374.

$672in general payments, 2019–2025

Across 33 payments — averaging $20.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$119
  • Lilly USA, LLC$84
  • Amgen$77
  • Sanofi$74
  • Johnson & Johnson$70
  • Regeneron Healthcare Solutions, Inc.$49
  • plus $198 from 8 others

What the payments were for

  • Food & beverage$64696%
  • Education$264%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$672 in reported general payments places this provider in the 25th percentile of 460 dermatology providers in Ohio.

See all dermatology providers in Ohio →

Medicare billing

Part B allowed, 2024
$105,964
Medicare patients
459
Services billed
1,994

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cosentyx Sensoready (2 Pens)Secukinumab51$395,055
Humira(Cf) PenAdalimumab21$279,897
Taltz AutoinjectorIxekizumab40$271,020
Skyrizi PenRisankizumab-Rzaa12$251,956
Dupixent PenDupilumab62$235,703
Cosentyx Unoready PenSecukinumab12$141,170
Dupixent SyringeDupilumab16$61,168
Clobetasol Propionate134$5,810
Tacrolimus29$5,566
Fluocinonide77$4,169
Clindamycin Phosphate81$3,270
Ketoconazole172$2,867
Tretinoin39$2,596
Triamcinolone Acetonide123$2,241
Metronidazole22$1,381

Paid to pharmacies, not to this prescriber.

Other dermatology in Cleveland

See the full list for Ohio →

Where these figures come from

Is this you, or does something look wrong? →